{"id":"placebo-to-match-tiotropium","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=placebo to match tiotropium","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:56.345544+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:29:01.760405+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=placebo to match tiotropium","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:29:02.167432+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Muscarinic acetylcholine receptor M3 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:03.266047+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3545181/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:02.930107+00:00"}},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos contain no active pharmaceutical ingredient and produce no pharmacological effect. This particular placebo is engineered to mimic tiotropium's appearance, taste, inhalation device mechanism, and delivery characteristics to maintain blinding in randomized controlled trials, ensuring that neither patients nor researchers can distinguish it from the active drug based on sensory cues.","oneSentence":"This is an inert placebo formulation designed to match the physical and sensory characteristics of tiotropium inhalation powder for use in blinded clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:36:14.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:29:04.518639+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"name":"Control arm in clinical trials of tiotropium for chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT05113615","phase":"PHASE4","title":"Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2021-12-13","conditions":"Asthma","enrollment":12},{"nctId":"NCT04223843","phase":"PHASE4","title":"A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to Inhale","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-01-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":213},{"nctId":"NCT00528996","phase":"PHASE2","title":"An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-09-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2080},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT03084796","phase":"PHASE2","title":"A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-07-28","conditions":"COPD, Chronic Obstructive Pulmonary Disease","enrollment":733},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03028142","phase":"PHASE2","title":"The Effects of RPL554 in Addition to Tiotropium in COPD Patients","status":"COMPLETED","sponsor":"Verona Pharma plc","startDate":"2017-01","conditions":"Chronic Obstructive Pulmonary Disease Moderate","enrollment":30},{"nctId":"NCT02257385","phase":"PHASE3","title":"Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":967},{"nctId":"NCT02207829","phase":"PHASE3","title":"A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1017},{"nctId":"NCT00279019","phase":"PHASE1","title":"Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12-12","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":31},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT00999908","phase":"PHASE3","title":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":54},{"nctId":"NCT01533935","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":291},{"nctId":"NCT01533922","phase":"PHASE3","title":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":295},{"nctId":"NCT01559116","phase":"PHASE3","title":"Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":219},{"nctId":"NCT01634113","phase":"PHASE2","title":"Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":102},{"nctId":"NCT01383499","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-08","conditions":"Asthma","enrollment":101},{"nctId":"NCT00975195","phase":"PHASE4","title":"Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2488},{"nctId":"NCT01696058","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1137},{"nctId":"NCT01694771","phase":"PHASE3","title":"Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1134},{"nctId":"NCT00772538","phase":"PHASE3","title":"Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":"Asthma","enrollment":459},{"nctId":"NCT01696071","phase":"PHASE2","title":"Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-09","conditions":"Asthma","enrollment":98},{"nctId":"NCT02172781","phase":"PHASE1","title":"Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934},{"nctId":"NCT00523991","phase":"PHASE4","title":"Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":457},{"nctId":"NCT01122680","phase":"PHASE2","title":"Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Asthma","enrollment":105},{"nctId":"NCT00737100","phase":"PHASE2","title":"Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-09","conditions":"Cystic Fibrosis","enrollment":510},{"nctId":"NCT00525512","phase":"PHASE4","title":"Tiotropium In Exercise","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-08","conditions":"Pulmonary Disease, Chronic Obstructive, Exercise","enrollment":519},{"nctId":"NCT01179347","phase":"PHASE3","title":"Tiotropium Bromide in Cystic Fibrosis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Cystic Fibrosis","enrollment":464},{"nctId":"NCT01072396","phase":"PHASE4","title":"Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":126},{"nctId":"NCT00257452","phase":"PHASE1","title":"A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-10","conditions":"Healthy","enrollment":56},{"nctId":"NCT01202188","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2144},{"nctId":"NCT00949975","phase":"PHASE2","title":"A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":838},{"nctId":"NCT00578968","phase":"PHASE4","title":"Cardiac Limitations in Chronic Obstructive Pulmonary Disease: Benefits of Bronchodilation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":36},{"nctId":"NCT00615459","phase":"PHASE3","title":"A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active Control","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":169}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL3545181"},"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"placebo to match tiotropium","genericName":"placebo to match tiotropium","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is an inert placebo formulation designed to match the physical and sensory characteristics of tiotropium inhalation powder for use in blinded clinical trials. Used for Control arm in clinical trials of tiotropium for chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:29:04.518639+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}